ahlam1399
08-07-2015, 03:40 AM
Allergan CEO says better to leave discoveries to others
Aug 6 (Reuters) - Allergan, which is selling its generics business to focus on branded ***** and aesthetics products, aims to acquire or license products that have already shown promise in studies, and leave the riskier discovery process to small biotechs and academic researchers.
http://rc.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/rc/1/rc.img (http://rc.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/rc/1/rc.htm)
http://rc.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/rc/2/rc.img (http://rc.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/rc/2/rc.htm)
http://rc.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/rc/3/rc.img (http://rc.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/rc/3/rc.htm)
http://da.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/a2.img (http://da.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/a2.htm)
http://adchoice.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/ach.img (http://adchoice.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/ach.htm)http://pi.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/a2t.imghttp://pi2.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/a2t2.imghttp://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/48c68009/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=maI0S2V9Sr0:uhmPH-WrKqQ:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=maI0S2V9Sr0:uhmPH-WrKqQ:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=maI0S2V9Sr0:uhmPH-WrKqQ:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=maI0S2V9Sr0:uhmPH-WrKqQ:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=maI0S2V9Sr0:uhmPH-WrKqQ:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/maI0S2V9Sr0
Aug 6 (Reuters) - Allergan, which is selling its generics business to focus on branded ***** and aesthetics products, aims to acquire or license products that have already shown promise in studies, and leave the riskier discovery process to small biotechs and academic researchers.
http://rc.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/rc/1/rc.img (http://rc.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/rc/1/rc.htm)
http://rc.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/rc/2/rc.img (http://rc.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/rc/2/rc.htm)
http://rc.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/rc/3/rc.img (http://rc.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/rc/3/rc.htm)
http://da.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/a2.img (http://da.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/a2.htm)
http://adchoice.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/ach.img (http://adchoice.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/ach.htm)http://pi.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/a2t.imghttp://pi2.feedsportal.com/r/234566747401/u/49/f/654213/c/35217/s/48c68009/sc/28/a2t2.imghttp://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/48c68009/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=maI0S2V9Sr0:uhmPH-WrKqQ:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=maI0S2V9Sr0:uhmPH-WrKqQ:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=maI0S2V9Sr0:uhmPH-WrKqQ:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=maI0S2V9Sr0:uhmPH-WrKqQ:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=maI0S2V9Sr0:uhmPH-WrKqQ:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/maI0S2V9Sr0